Nubeqa plus androgen deprivation therapy displayed positive radiological progression-free survival results in early trial data. Among patients with metastatic hormone-sensitive prostate cancer, the ...
Erleada shows consistent 24-month overall survival in real-world settings and the TITAN trial for metastatic castration-sensitive prostate cancer. Erleada reduces the risk of death by 23% compared to ...
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...
Feasibility and acceptability of remote activity and patient-reported outcome monitoring in men with prostate cancer undergoing androgen deprivation therapy. Circulating tumor cells and clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results